Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€3.62
€0.10(13.73%)
At close: 4:00 PM EST
€3.62
€0.10(13.73%)
Day’s Range― - ―
52-Week Range€1.45 - €4.50
Previous CloseN/A
Volume1.76M
Average Volume (3M)1.12M
Market Cap
€732.31M
Enterprise Value€1.09K
Total Cash (Recent Filing)€174.90M
Total Debt (Recent Filing)€21.80M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Oct 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding296,061,500
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.50Price Target Upside51.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€3.84M
Bulls Say, Bears Say
Bulls Say
Proprietary EPIT PlatformDBV's proprietary EPIT patch platform and lead program (Viaskin Peanut) represent a durable technology moat in a high unmet-need allergy market. A successful platform can be scaled across multiple food allergens, enabling repeatable product launches and higher long-term operating leverage if clinical success is achieved.
Low Financial LeverageA low debt burden relative to equity provides structural solvency resilience versus more levered biotech peers. This balance sheet strength reduces near-term default risk, supports continued R&D investment, and extends runway for clinical programs before additional financing is required.
Improving Free Cash Flow TrendAlthough FCF remains negative, the positive TTM growth trend indicates operational cash outflows are moderating. Coupled with FCF aligning closely with reported net losses, this trend suggests cash burn is tracking real expenses, which modestly improves runway planning and capital allocation decisions.
Bears Say
Large Ongoing Cash BurnPersistent, very large negative operating and free cash flows create structural financing dependence. Continued burn at this magnitude will require material new capital, raising dilution and execution risk for multi-year clinical programs and constraining strategic flexibility absent clear near-term revenue inflection.
Minimal And Volatile RevenueNear-zero and inconsistent revenue means the company lacks commercial cash generation, making long-term viability contingent on clinical success or external financing. This structural lack of diversified revenue amplifies reliance on trial outcomes and partnerships for sustainable business scaling.
Negative Returns On EquityA deeply negative ROE signals the company is eroding shareholder capital rather than compounding it. Over the medium term, persistent negative returns limit ability to build retained earnings, increase pressure for dilutive financing, and undermine long-term investor return prospects absent a clinical or commercial inflection.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.45 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €732.31M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Oct 28, 2026 which is in 97 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Jul 16, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of -€0.019 by -€0.002.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Undervalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 296,061,500 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.021 in its last earnings report, missing expectations of -€0.019. Following the earnings report the stock price went down -7.275%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
DBV Stock 12 Month Forecast
Average Price Target
€5.50
▲(51.93% Upside)